A detailed history of Nisa Investment Advisors, LLC transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 1,136 shares of KURA stock, worth $10,155. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,136
Previous 1,124 1.07%
Holding current value
$10,155
Previous $23,000 4.35%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$18.57 - $23.23 $222 - $278
12 Added 1.07%
1,136 $22,000
Q2 2024

Jul 19, 2024

BUY
$17.53 - $22.98 $1,121 - $1,470
64 Added 6.04%
1,124 $23,000
Q1 2024

May 01, 2024

BUY
$13.42 - $23.53 $939 - $1,647
70 Added 7.07%
1,060 $22,000
Q4 2023

Jan 25, 2024

BUY
$7.58 - $14.38 $121 - $230
16 Added 1.64%
990 $14,000
Q3 2023

Nov 02, 2023

SELL
$8.44 - $11.86 $126 - $177
-15 Reduced 1.52%
974 $8,000
Q2 2023

Aug 11, 2023

SELL
$9.62 - $13.99 $12,852 - $18,690
-1,336 Reduced 57.46%
989 $10,000
Q1 2023

May 02, 2023

BUY
$10.71 - $14.6 $14,833 - $20,221
1,385 Added 147.34%
2,325 $28,000
Q4 2022

Feb 02, 2023

SELL
$11.23 - $16.9 $595 - $895
-53 Reduced 5.34%
940 $12,000
Q3 2022

Nov 07, 2022

SELL
$12.01 - $19.45 $27,586 - $44,676
-2,297 Reduced 69.82%
993 $15,000
Q2 2022

Aug 03, 2022

BUY
$10.71 - $18.33 $15,743 - $26,945
1,470 Added 80.77%
3,290 $60,000
Q1 2022

Apr 29, 2022

BUY
$11.78 - $16.98 $14,371 - $20,715
1,220 Added 203.33%
1,820 $29,000
Q2 2021

Aug 06, 2021

SELL
$20.85 - $29.88 $46,912 - $67,230
-2,250 Reduced 78.95%
600 $13,000
Q1 2021

Apr 26, 2021

SELL
$24.75 - $39.14 $9,281 - $14,677
-375 Reduced 11.63%
2,850 $81,000
Q4 2020

Jan 25, 2021

BUY
$29.0 - $41.62 $31,175 - $44,741
1,075 Added 50.0%
3,225 $105,000
Q3 2020

Oct 20, 2020

BUY
$16.3 - $30.64 $35,045 - $65,876
2,150 New
2,150 $66,000

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $598M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.